QuidelOrtho
QuidelOrtho (NASDAQ: QDEL) is a publicly traded in vitro diagnostics company serving clinical labs, hospitals, blood banks, and point-of-care settings with 550+ assays spanning clinical chemistry, immunoassay, molecular, point-of-care, and immunohematology across 140+ countries.
- Company typePublic
- Founded2022
- HeadquartersSan Diego, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What QuidelOrtho does
QuidelOrtho Corporation is a publicly traded in vitro diagnostics company (NASDAQ: QDEL) headquartered in San Diego, California, formed in 2022 through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The company develops, manufactures, and markets diagnostic products across five core technology areas: clinical chemistry and immunoassay (VITROS systems), point-of-care testing (SOFIA, QUICKVUE, TRIAGE), immunohematology and donor screening (ORTHO VISION Swift, ORTHO Workstation, ORTHO Summit), molecular diagnostics (SOLANA, LYRA, and the newly acquired LEX VELO ultra-fast PCR platform), and specialty/research products (MICROVUE). With approximately 550 assays and a presence in 140+ countries, QuidelOrtho serves clinical laboratories, hospital labs, reference labs, blood banks, physician offices, pharmacies, and consumers, positioning itself as a broad-menu diagnostics provider spanning from centralized labs to point-of-care settings.
The company generates revenue through the sale of diagnostic instruments and analyzers (hardware) along with associated reagents, consumables, and assay kits, with the consumables stream providing recurring revenue from the installed base. QuidelOrtho distributes through a direct enterprise field sales force targeting laboratory professionals and healthcare providers, complemented by the Ortho Plus customer portal, regional distributor networks internationally, and strategic supply partnerships (notably Lifotronic Technology for immunoassay expansion outside the United States). Pricing is quote-based for enterprise laboratory customers and typically structured through reagent rental or volume-tied purchase agreements, while research-use specialty products carry listed unit pricing.
Financially, QuidelOrtho reported FY2025 revenue of approximately $2.73 billion with a Q1 2026 revenue decline of 10.5% year-over-year to $620 million, driven by weaker respiratory testing demand. The company carries $2.87 billion in total debt, faces margin compression (Q1 2026 adjusted EBITDA margin of 17.5% versus 23.1% prior year), and is pursuing operational stabilization through recent leadership additions, the LEX Diagnostics acquisition, new product launches, and international distribution expansion.
QuidelOrtho firmographics
Firmographics- Name
- QuidelOrtho
- Legal name
- QuidelOrtho Corporation
- Website
- https://quidelortho.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- QuidelOrtho (NASDAQ: QDEL) is a publicly traded in vitro diagnostics company serving clinical labs, hospitals, blood banks, and point-of-care settings with 550+ assays spanning clinical chemistry, immunoassay, molecular, point-of-care, and immunohematology across 140+ countries.
- Ownership category
- akta.pro rank
QuidelOrtho industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)
Keywords
Where QuidelOrtho is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
QuidelOrtho business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Revenue model
- Diagnostic Products and Consumables: QuidelOrtho generates revenue through the sale of diagnostic instruments/systems, reagents, consumables, and assay kits across its portfolio of testing platforms including VITROS systems, SOFIA, ORTHO VISION, QUICKVUE, TRIAGE, and molecular diagnostics. The consumables segment typically generates higher profit margins than equipment sales and drives recurring revenue through established instrument installed base.
- Laboratory Testing Services: The Labs segment represents approximately 55% of company sales, providing clinical laboratory testing solutions and immunohematology testing for blood compatibility in transfusion medicine.
- Point-of-Care Testing: Point-of-care diagnostic products including rapid tests and portable testing systems for use in physician offices, pharmacies, and other near-patient settings.
- Donor Screening: Blood donor screening solutions for transfusion safety, including immunohematology testing and donor immunoassay testing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | MICROVUE Specialty Products Group ELISA and research products |
| Other | Multi-year contract | Enterprise/laboratory diagnostic systems |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
QuidelOrtho product offering
Product offeringCore offering
QuidelOrtho develops, manufactures, and markets diagnostic instruments, reagents, and consumables spanning clinical chemistry, immunoassay, molecular diagnostics, point-of-care testing, and immunohematology (transfusion medicine/blood banking). The company offers automated analyzers (e.g., VITROS, ORTHO VISION Swift), rapid lateral-flow tests (QUICKVUE, SOFIA), PCR assays (LYRA, SOLANA, LEX VELO), and supporting middleware software, sold primarily to hospital laboratories, reference labs, blood banks, and physician offices across 140+ countries.
Product overview
QuidelOrtho offers a comprehensive in vitro diagnostics portfolio spanning multiple technology platforms and testing categories. The core portfolio includes the VITROS clinical chemistry and immunoassay systems, SOFIA rapid testing platform, ORTHO immunohematology systems (including ORTHO VISION Swift automated analyzer and ORTHO Workstation semi-automated system), QUICKVUE rapid lateral-flow tests, and TRIAGE point-of-care system. Molecular diagnostics are served through the SOLANA platform, LYRA assays, and the newly acquired LEX VELO ultra-fast PCR system. The company also offers specialized product lines including MICROVUE complement and immune monitoring assays, D3 virus testing solutions, and ELVIS HSV testing. Supporting infrastructure includes ORTHO CONNECT lab management middleware software for LIS connectivity, ORTHO Summit donor screening systems, and various reagent menus. With approximately 550 assays offered across 140+ countries, the platform-plus-modules architecture enables customers to select from automated, semi-automated, and rapid testing solutions depending on throughput needs and laboratory setting.
Differentiator
Problem solved
Functional benefit
Brands
- VITROS: Clinical chemistry and immunoassay systems enabling fast, accurate and reliable results
- SOFIA
- ORTHO VISION
- ORTHO Workstation
- QUICKVUE
- TRIAGE
- LYRA
- MICROVUE
- ORTHO CONNECT
- ORTHO OPTIX
- SOLANA
- SAVANNA
- VIRENA
- ELVIS
- Science Bytes Podcast
Products and services
- VITROS Systems
Companies that use QuidelOrtho
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
QuidelOrtho technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature8 records
QuidelOrtho partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Allo Hope FoundationcoreQuidelOrtho and the Allo Hope Foundation announced a collaboration to improve prenatal care for alloimmunized pregnancies and hemolytic disease of the fetus and newborn (HDFN). The organizations will jointly develop educational materials for lab technicians and families, addressing gaps in care that disproportionately affect underserved populations with the goal of improving early testing and equitable access to specialized treatment.
- Lifotronic Technology Co., Ltd.coreQuidelOrtho entered a long-term strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio. The collaboration provides access to multiple high-throughput and low-to-mid volume analyzer platforms with over 70 assays, including more than 25 new assays not currently available on the VITROS system. Commercial focus covers Europe, Middle East, Africa, Latin America, India, China, Japan, and Asia-Pacific regions.
- Azer ScientificminorQuidelOrtho (as Quidel Corp) was involved in a legal dispute with Azer Scientific regarding force majeure and supply commitments. The court found that explicit email confirmations with reliance can enforce commitments even without a signed master agreement.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
QuidelOrtho competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Roche runs the cobas family of clinical chemistry/immunoassay analyzers and a broad molecular diagnostics portfolio (cobas Liat, cobas 6800/8800), competing head-to-head with QuidelOrtho's VITROS immunoassay systems and LEX VELO rapid PCR in hospital and reference-lab channels globally.
- Siemens Healthineers: Siemens Healthineers offers the Atellica CH/IM clinical chemistry/immunoassay platform and a broad IVD menu, directly comparable to QuidelOrtho's VITROS installed base and competitive with QDEL's core laboratory automation strategy.
- Becton Dickinson (BD): BD offers the BD Veritor rapid antigen testing system, BD MAX molecular platform, and a broad microbiology/immunohematology portfolio, overlapping with QuidelOrtho's QUICKVUE rapid tests, LYRA/SOLANA molecular assays, and immunohematology franchise.
- Beckman Coulter Diagnostics (Danaher): Beckman Coulter's DxC/DxI clinical chemistry and immunoassay analyzers and Access immunoassay systems compete directly with QuidelOrtho's VITROS franchise in mid- and high-volume hospital laboratories worldwide.
- Abbott Diagnostics: Abbott operates a large diagnostics division with the Architect and Alinity ci-series clinical chemistry/immunoassay systems, the Binax rapid test franchise, and the i-STAT POC system—directly comparable to QuidelOrtho's VITROS, SOFIA, and TRIAGE platforms across hospital labs and near-patient settings.
Direct peers
- bioMérieux: bioMérieux's VITEK and BIOBALYS systems serve microbiology and infectious disease diagnostics—comparable use cases to QuidelOrtho's molecular diagnostics (LYRA, SOLANA, LEX VELO), TRIAGE infectious disease menu, and donor screening solutions.
- Cepheid (Danaher): Cepheid's GeneXpert rapid molecular PCR platform with Xpress-style workflows is the closest direct competitor to QuidelOrtho's LEX VELO ultra-fast PCR system in clinic, pharmacy, and hospital POC molecular testing.
- Hologic: Hologic's Panther and Panther Fusion molecular diagnostics systems and the Binx io rapid molecular platform are comparable to QuidelOrtho's SOLANA, LYRA, and the newly acquired LEX VELO ultra-fast PCR in infectious disease and women's health testing.
- Bio-Rad Laboratories: Bio-Rad's clinical chemistry/immunoassay controls, quality management software (Unity Real Time), and blood bank reagents compete with QuidelOrtho's MICROVUE specialty assays and ORTHO VISION/Workstation blood bank offerings across lab QC and immunohematology.
Regional players
- Mindray Bio-Medical: Mindray offers BC-7500/CS-7500 clinical chemistry and immunoassay analyzers with strong penetration in China, EMEA, and emerging markets, competing with QuidelOrtho's VITROS in price-sensitive international segments served via the Lifotronic partnership.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
QuidelOrtho social profiles
Digital presenceQuidelOrtho compliance and trust
Trust signalCompliance5 records
QuidelOrtho financial estimates
Financial estimateRevenue estimate
Valuation estimate
QuidelOrtho leadership team
Management profileNumber of profiles
Profiles9 records
QuidelOrtho subsidiaries and ownership
Company hierarchySubsidiaries1 record
QuidelOrtho funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QuidelOrtho M&A and investment
M&A and investmentM&A12 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QuidelOrtho
What does QuidelOrtho do?
QuidelOrtho develops, manufactures, and markets diagnostic instruments, reagents, and consumables spanning clinical chemistry, immunoassay, molecular diagnostics, point-of-care testing, and immunohematology (transfusion medicine/blood banking). The company offers automated analyzers (e.g., VITROS, ORTHO VISION Swift), rapid lateral-flow tests (QUICKVUE, SOFIA), PCR assays (LYRA, SOLANA, LEX VELO), and supporting middleware software, sold primarily to hospital laboratories, reference labs, blood banks, and physician offices across 140+ countries.
Is QuidelOrtho a public or private company?
QuidelOrtho is a public company. It is classified as public and is currently operating.
When was QuidelOrtho founded?
QuidelOrtho was founded in 2022. It employs 1,001 to 5,000 people.
Where is QuidelOrtho based?
QuidelOrtho is headquartered in San Diego, United States, in the North America region.
How does QuidelOrtho make money?
Four revenue lines are on record. Diagnostic Products and Consumables are the primary driver. The others are laboratory Testing Services, point-of-Care Testing and donor Screening.
Who are QuidelOrtho's main competitors?
Broad incumbents on record are Roche Diagnostics, Siemens Healthineers, Becton Dickinson (BD), Beckman Coulter Diagnostics (Danaher) and Abbott Diagnostics. Direct peers are bioMérieux, Cepheid (Danaher), Hologic and Bio-Rad Laboratories. Mindray Bio-Medical is listed as a regional player.
Does QuidelOrtho have an API?
No public API is recorded for QuidelOrtho.
What industry is QuidelOrtho in?
QuidelOrtho's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 325413 and its SIC code is 2835.